Huntington National Bank Sells 32,116 Shares of Pfizer Inc. $PFE

Huntington National Bank trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 537,293 shares of the biopharmaceutical company’s stock after selling 32,116 shares during the quarter. Huntington National Bank’s holdings in Pfizer were worth $13,690,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. grew its position in Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after acquiring an additional 10,198,330 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Pfizer by 1.4% during the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after acquiring an additional 1,820,634 shares during the period. Norges Bank acquired a new stake in shares of Pfizer in the 2nd quarter valued at $2,270,157,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Pfizer by 2.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after purchasing an additional 1,135,457 shares during the last quarter. Finally, Fisher Asset Management LLC grew its holdings in shares of Pfizer by 2.0% in the 2nd quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock worth $1,172,980,000 after purchasing an additional 950,239 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

PFE stock opened at $27.61 on Friday. The company has a 50 day moving average price of $26.13 and a 200 day moving average price of $25.41. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The stock has a market capitalization of $156.97 billion, a PE ratio of 20.30 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the company earned $0.63 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on PFE shares. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Citigroup assumed coverage on Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price on the stock. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research report on Thursday, February 12th. Finally, Morgan Stanley dropped their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $27.70.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a Phase 2 study of an mRNA influenza vaccine, advancing its mRNA platform into a large seasonal market — a successful program could drive multi-year upside and higher-margin sales. Pfizer Advances mRNA Flu Vaccine Pipeline With New Phase 2 Trial
• Positive Sentiment: Pfizer updated a Phase 1 study for a new obesity injectable — progress in obesity therapeutics targets a very large market and would materially diversify revenue if clinical development continues to advance. Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update
• Positive Sentiment: The FDA granted full approval to Pfizer’s BRAFTOVI regimen for first‑line treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC), converting prior accelerated approval — this expands the label and reduces regulatory risk, supporting near‑term oncology sales. Pfizer Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC
• Positive Sentiment: Income-focused narratives are supporting demand: coverage and write-ups highlighting Pfizer’s attractive dividend (yield cited >6% by some outlets) are drawing investor interest into the stock as a yield play. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%
• Neutral Sentiment: Analysts at Zacks moved Pfizer from “strong sell” to “hold,” which reduces immediate downside narrative but is not a strong buy signal. Zacks upgrade to Hold
• Neutral Sentiment: Recent quarterly results beat EPS and revenue estimates, showing operating resilience despite slight year‑over‑year revenue decline — supports the stock’s valuation but doesn’t eliminate structural concerns.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of a projected $15B–$20B structural revenue decline through 2030 — this report injects a bearish, long‑term revenue risk narrative that can cap upside. RBC Initiates with $25 Target

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.